Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies

Journal of Chemotherapy

Volumn 16, Issue 2, 2004, Pages 206-210

  Correale, P ^a   Cerretani, D ^a   Clerici, M ^b   Messinese, S ^a   Marsili, S ^a   Petrioli, R ^a   Cetta, F ^a   Savelli, V ^a   Guarnieri, A ^a   Pinto, E ^a   Giorgi, G ^a   Francini, G ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b San Giuseppe Hospital   (Italy)

Author keywords

5 Fluorouracil; Gastroenteric malignancies; Gemcitabine; Pancreas carcinoma

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG SCREENING; DRUG SPECIFICITY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOTENSION; INTESTINE INFARCTION; LIVER DISEASE; MALE; MUCOSA INFLAMMATION; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; STOMACH CARCINOMA; STOMACH HEMORRHAGE; UREA NITROGEN BLOOD LEVEL;

EID: 2942536831     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.2.206     Document Type: Article

References (31)

1. th Edition. Philadelphia: Lippincott Williams and Wilkins, 2001; 388-415.
2. Grem JL, Takimoto CH, Multani P, et al. Antimetabolites. Cancer Chemother Biol Response Modif 1999; 18: 1-38.
3. Moran RG, Scanlon KL. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 1991; 51: 4618-4623.
4. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23 (Suppl 10): 3-15.
5. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87 (2-3): 227-253.
6. Schulz L, Schalhorn A, Wilmanns W, Heinemann V. Synergistic interaction of dFdC and 5-FU in colon cancer cells. Proc Ann Met Am Soc Clin Oncol 1998; 17: 251a (abstract).
7. th Ann Met Am Assoc Cancer Res 1999; 38.2243 (abstract).
8. Hidalgo M, Castellano D, Paz-Ares L, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17 (2): 585-592.
9. Berlin JD, Alberti DB, Arzoomanian RZ, et al. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Invest New Drugs 1998-99; 16 (4): 325-330.
10. Cascinu S, Silva RR, Barni S, et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1999; 80: 1595-1598.
11. Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 2002; 95: 912-922.
12. Barone C, Cassano A, Corsi DC, et al. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study. Oncology 2003; 64(2): 139-145.
13. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275.
14. Correale P, Cerretani D, Marsili S, et al. Gemcitabine increases 5-fluorouracil systemic exposure in advanced cancer patients: pharmacokinetic considerations. Eur J Cancer 2003; 39: 1547-1551.
15. World Health Organization WHO. Handbook for reporting results of cancer treatment. Geneve. World Health Organization, 1979.
16. Rocha Lima CM, Centeno B. Update on pancreatic cancer. Curr Opin Oncol 2002; 14: 424-430.
17. Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomized, multicentre trial. Br Med J 1980; 281: 1589-1591.
18. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253: 2061-2067.
19. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995; 31A (6): 882-887.
20. Heinemann V. Present and future treatment of pancreatic cancer. Semin Oncol 2002; 29: 23-31.
21. Cohen SJ, Pinover WH, Watson JC, Meropol NJ. Pancreatic cancer. Curr Treat Options Oncol 2002; 1: 375-386.
22. Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.
23. Scheithauer W, Kornek GV, Raderer M, et al. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 1999; 80: 1797-1802.
24. Jacobs AD. Gemcitabine-based therapy in pancreas cancer: Gemcitabine-docetaxel and other novel combinations. Cancer 2002; 95: 923-927.
25. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20(6): 512-518.
26. th Edition. Philadelphia: Lippincott Williams and Wilkins, 2001: 1216-1271.
27. Madajewicz S, Hentschel P, Burns P, et al. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J Clin Oncol 2000; 18(20): 3553-3537.
28. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol 2002; 29 (6 Suppl 20): 40-45.
29. Young AM, Darayanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil? Clin Pharmacokinet 1999; 36(6): 391-398.
30. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4: 2039-2045.
31. th International Congress on Anti-Cancer Treatment (ICACT-Paris, France) 2000, 293 (abstract).